EZH2 is Overexpressed in Laryngeal Squamous Cell Carcinoma and Enhances the Stem-like Properties of AMC-HN-8 Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2016 Jul 23

PMID 27446358

Citations 9

Authors

Jiameng Huang

Liang Zhou

Hui Chen

Chunping Wu

Zhang Duo

Yanping Zhang

Affiliations

Soon will be listed here.

Abstract

The enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) histone methyltransferase is the catalytic subunit of polycomb repressive complex 2 (PRC2), which is important for epigenetic regulation. EZH2 is highly expressed in various types of tumors, and its high-level expression promotes the progression and invasion of certain tumors. However, the expression level of EZH2 and its functions in laryngeal squamous cell carcinomas are unknown. In the present study, the level of EZH2 expression in laryngeal squamous cell carcinomas was evaluated using immunochemical staining and reverse transcription-quantitative polymerase chain reaction. EZH2 was overexpressed in AMC-HN-8 cells with lentiviral transfection. Cell proliferation, apoptosis, cell-cycle, chemotherapy-sensitivity and tumorigenic assays were performed. The results indicated that EZH2 was highly expressed in laryngeal squamous cell carcinomas. Additionally, EZH2 overexpression promoted proliferation, accelerated cell-cycle progression and enhanced the tumorigenicity in laryngeal squamous cancer cells. More importantly, EZH2 enhanced the chemotherapy resistance of these cells. Overall, the results indicated that EZH2 promotes the progression of laryngeal squamous cell cancer and could be a potential chemotherapeutic target for the treatment of such cancer.

Citing Articles

The association between lncRNA H19 and EZH2 expression in patients with EBV-positive laryngeal carcinoma.

Hotoboc I, Fudulu A, Grigore R, Bertesteanu S, Huica I, Iancu I Acta Otorhinolaryngol Ital. 2021; 41(6):537-543.

PMID: 34825669 PMC: 8686793. DOI: 10.14639/0392-100X-N1527.

Epigenetic Modifiers as Novel Therapeutic Targets and a Systematic Review of Clinical Studies Investigating Epigenetic Inhibitors in Head and Neck Cancer.

Burkitt K, Saloura V Cancers (Basel). 2021; 13(20).

PMID: 34680389 PMC: 8534083. DOI: 10.3390/cancers13205241.

Hsa_circ_0006232 promotes laryngeal squamous cell cancer progression through FUS-mediated EZH2 stabilization.

Wu T, Wang G, Zeng X, Sun Z, Li S, Wang W Cell Cycle. 2021; 20(18):1799-1811.

PMID: 34437823 PMC: 8525971. DOI: 10.1080/15384101.2021.1959973.

Horizontal transfer of the stemness-related markers EZH2 and GLI1 by neuroblastoma-derived extracellular vesicles in stromal cells.

Villasante A, Godier-Furnemont A, Hernandez-Barranco A, Le Coq J, Boskovic J, Peinado H Transl Res. 2021; 237:82-97.

PMID: 34217898 PMC: 9204390. DOI: 10.1016/j.trsl.2021.06.006.

Protein Post-translational Modifications in Head and Neck Cancer.

Zhang H, Han W Front Oncol. 2020; 10:571944.

PMID: 33117703 PMC: 7561398. DOI: 10.3389/fonc.2020.571944.

References

Rizzo S, Hersey J, Mellor P, Dai W, Santos-Silva A, Liber D . Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther. 2011; 10(2):325-35. PMC: 3037846. DOI: 10.1158/1535-7163.MCT-10-0788. View

Suva M, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle J . EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009; 69(24):9211-8. DOI: 10.1158/0008-5472.CAN-09-1622. View

Wagener N, Macher-Goeppinger S, Pritsch M, Husing J, Hoppe-Seyler K, Schirmacher P . Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer. 2010; 10:524. PMC: 2958940. DOI: 10.1186/1471-2407-10-524. View

van Vlerken L, Kiefer C, Morehouse C, Li Y, Groves C, Wilson S . EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Stem Cells Transl Med. 2013; 2(1):43-52. PMC: 3659740. DOI: 10.5966/sctm.2012-0036. View

Sher F, Rossler R, Brouwer N, Balasubramaniyan V, Boddeke E, Copray S . Differentiation of neural stem cells into oligodendrocytes: involvement of the polycomb group protein Ezh2. Stem Cells. 2008; 26(11):2875-83. DOI: 10.1634/stemcells.2008-0121. View

Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K . High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol. 2008; 45(1):39-46. DOI: 10.1016/j.oraloncology.2008.03.016. View

Zhao L, Yu Y, Wu J, Bai J, Zhao Y, Li C . Role of EZH2 in oral squamous cell carcinoma carcinogenesis. Gene. 2014; 537(2):197-202. DOI: 10.1016/j.gene.2014.01.006. View

Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C . The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2005; 439(7078):871-4. DOI: 10.1038/nature04431. View

Ezhkova E, Pasolli H, Parker J, Stokes N, Su I, Hannon G . Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell. 2009; 136(6):1122-35. PMC: 2716120. DOI: 10.1016/j.cell.2008.12.043. View

10.

Meng X, Huang Z, Wang R, Jiao Y, Li H, Xu X . The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy. Radiat Oncol. 2014; 9:188. PMC: 4163172. DOI: 10.1186/1748-717X-9-188. View

11.

Chen H, Xin Y, Zhou L, Huang J, Tao L, Cheng L . Cisplatin and paclitaxel target significant long noncoding RNAs in laryngeal squamous cell carcinoma. Med Oncol. 2014; 31(11):246. DOI: 10.1007/s12032-014-0246-7. View

12.

Bachmann I, Halvorsen O, Collett K, Stefansson I, Straume O, Haukaas S . EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2005; 24(2):268-73. DOI: 10.1200/JCO.2005.01.5180. View

13.

Majewski I, Blewitt M, de Graaf C, McManus E, Bahlo M, Hilton A . Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity. PLoS Biol. 2008; 6(4):e93. PMC: 2292752. DOI: 10.1371/journal.pbio.0060093. View

14.

LeBlanc B, Shi R, Mehta V, Mills G, Ampil F, Nathan C . Improvements in survival and disparities for advanced-stage laryngeal cancer. JAMA Otolaryngol Head Neck Surg. 2014; 141(2):169-73. DOI: 10.1001/jamaoto.2014.2998. View

15.

Wan L, Li X, Shen H, Bai X . Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics. Clin Transl Oncol. 2012; 15(2):132-8. DOI: 10.1007/s12094-012-0897-9. View

16.

Li K, Liu C, Zhou B, Bi L, Huang H, Lin T . Role of EZH2 in the growth of prostate cancer stem cells isolated from LNCaP cells. Int J Mol Sci. 2013; 14(6):11981-93. PMC: 3709767. DOI: 10.3390/ijms140611981. View

17.

Shi Y, Gong H, Zhou L, Tian J, Wang Y . CD24: a novel cancer biomarker in laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2012; 74(2):78-85. DOI: 10.1159/000335584. View

18.

McCabe M, Ott H, Ganji G, Korenchuk S, Thompson C, Van Aller G . EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492(7427):108-12. DOI: 10.1038/nature11606. View

19.

Lee T, Jenner R, Boyer L, Guenther M, Levine S, Kumar R . Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006; 125(2):301-13. PMC: 3773330. DOI: 10.1016/j.cell.2006.02.043. View

20.

Wu Z, Lee S, Qiao Y, Li Z, Lee P, Lee Y . Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ. 2011; 18(11):1771-9. PMC: 3190113. DOI: 10.1038/cdd.2011.48. View